News

Financial Results Q3 FY12/16
Financial Results Q3 FY12/16

Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2016
Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2016

Chiome Bioscience signs Material Transfer Agreement (MTA) with National Cancer Institute to evaluate its anti-DLK-1 antibody within Pediatric Preclinical Testing Consortium
Chiome Bioscience signs Material Transfer Agreement (MTA) with National Cancer Institute to evaluate its anti-DLK-1 antibody within Pediatric Preclinical Testing Consortium

Supplement Documents for Financial Results Q2 FY12/16
Supplement Documents for Financial Results Q2 FY12/16

Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2016
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2016

Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31, 2016
Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31, 2016

Supplement Documents for Financial Results Q1 FY12/16
Supplement Documents for Financial Results Q1 FY12/16

Execution of the Option License Agreement for LIV-2008b, an anti-cancer antibody developed by Chiome Bioscience
Execution of the Option License Agreement for LIV-2008b, an anti-cancer antibody developed by Chiome Bioscience

Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2015
Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2015

Supplement Documents for Financial Results FY12/15
Supplement Documents for Financial Results FY12/15